HDL Subtractions Distribution in Renal Transplant Recipients: Lack of Evidence of a Reduction of HDL&lt;sub&gt;2&lt;/sub&gt; Particles

Barbagallo, Carlo A.; Averna, Maurizio; Sparacino, Vito; Cefalù, Angelo Baldassare; Caputo, Flavia; Noto, Davide; Verghi, F.; Notarbartoló, A

doi:10.1159/000188904

Cited by 7 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In RTR, the main lipid alteration is hypercholesterolemia [87,90], while hypertriglyceridemia is less pronounced. HDL cholesterol levels has been found normal or high in this category of subjects; HDL subfractions are variable since some researchers have demonstrated low levels of HDL2 [91] while others failed to show any decrease of HDL2 particles [92]. Lp(a) are only slightly increased when kidney function improves [15], but its metabolism is not completely known.…”

Section: Renal Transplantationmentioning

confidence: 86%

Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation

Barbagallo

Cefalù

Giammanco

et al. 2021

Life

Self Cite

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is one of the most important risk factors for cardiovascular disease (CVD). Despite the kidney having no direct implications for lipoproteins metabolism, advanced CKD dyslipidemia is usually present in patients with CKD, and the frequent lipid and lipoprotein alterations occurring in these patients play a role of primary importance in the development of CVD. Although hypertriglyceridemia is the main disorder, a number of lipoprotein abnormalities occur in these patients. Different enzymes pathways and proteins involved in lipoprotein metabolism are impaired in CKD. In addition, treatment of uremia may modify the expression of lipoprotein pattern as well as determine acute changes. In renal transplantation recipients, the main lipid alteration is hypercholesterolemia, while hypertriglyceridemia is less pronounced. In this review we have analyzed lipid and lipoprotein disturbances in CKD and also their relationship with progression of renal disease. Hypolipidemic treatments may also change the natural history of CVD in CKD patients and may represent important strategies in the management of CKD patients.

show abstract

Section: Renal Transplantationmentioning

confidence: 86%

Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation

Barbagallo

Cefalù

Giammanco

et al. 2021

Life

Self Cite

View full text Add to dashboard Cite

show abstract

“…This abnormality is not corrected by hemodialysis and persists also after kidney transplantation [ 27 ]. It has also been demonstrated that renal transplant recipients presented significantly lower levels of HDL3a and HDL3b and, in males, higher levels of HDL2b than controls [ 28 ]. Our results confirm these data.…”

Section: Discussionmentioning

confidence: 99%

Changes in serum pigment epithelium-derived factor levels after kidney transplantation in patients with end-stage renal disease

et al. 2022

View full text Add to dashboard Cite

Background Pigment epithelium-derived factor (PEDF) is a serin protease inhibitor and a potent inhibitor of angiogenesis. Its serum level has significant associations with metabolic parameters. However, little is known about the association between PEDF levels and lipid parameters in renal transplanted (TX) patients. Therefore, our aim was to investigate the relationship between PEDF level and lipid parameters in TX patients. Methods Seventy TX patients (47 males, 23 females, mean age 51.7 ± 12.4 years) and 34 healthy controls were enrolled. We examined the serum creatinine, C-reactive protein, fasting glucose and lipid parameters right before, then 1 and 6 months after TX. High-density lipoprotein (HDL)-associated paraoxonase-1 (PON1) activities were measured spectrophotometrically. Lipoprotein subfractions were determined by Lipoprint. PEDF and oxidized low-density liporotein (oxLDL) levels were measured by ELISA. Results Before transplantation, patients had had a significantly higher PEDF level compared to control subjects ( p < 0.001). One month after transplantation, their PEDF level decreased significantly reaching the healthy controls’ level, and this lower level was maintained during the 6 months follow-up period as well. The initial oxLDL level was significantly higher, while PON1 activities were significantly lower in the patient group compared to the control group. We found a significant positive correlation between PEDF and total cholesterol, low-density lipoprotein (LDL)-cholesterol, triglyceride, oxLDL and small HDL subfraction; while negative correlations were found between PEDF and mean LDL size and large HDL subfraction during the entire follow-up period. Conclusion PEDF may play an important role in the increased oxidative stress and enhanced atherogenesis in renal transplant patients.

show abstract

“…As major metabolic risk factor for CHD, HDL-C has recently been qualified in a prospective study as the best lipid-related predictor of CHD in RTX [1]. However, very heterogeneous HDL-C levels have been reported in RTX, and the mechanisms underlying the marked individual differences are poorly understood [4, 5, 21]. Genetic family studies suggest that 40–60% of the variation of HDL-C between individuals is determined by genetic factors [24].…”

Section: Discussionmentioning

confidence: 99%

“…However, unexpected results have been reported concerning serum HDL-C levels in RTX patients. Indeed, although decreased HDL-C levels have been reported [2], most studies have found normal or slighly elevated HDL-C levels in RTX, a paradoxical finding in a patient population characterized by a high prevalence of hyperlipidemia and accelerated atherosclerosis [3, 4, 5]. These conflicting data on HDL-C levels and their relationship with CHD in RTX suggest poorly understood and complex interactions between the immunosuppressive therapy and the metabolic and/or genetic factors determining HDL-C levels in this patient population.…”

Section: Introductionmentioning

confidence: 99%

HDL Cholesterol and TaqIB Cholesteryl Ester Transfer Protein Gene Polymorphism in Renal Transplant Recipients

Radeau

Vohl²,

Houde³

et al. 2000

Nephron

View full text Add to dashboard Cite

Decreased serum levels of high-density lipoprotein cholesterol (HDL-C) are a well-known risk factor for coronary heart disease (CHD) in the general population and have been suggested as one of the best predictor of CHD after renal transplantation. However, very heterogeneous HDL-C levels have been reported in renal transplant recipients. In this patient population, serum HDL-C levels are determined by complex interactions between hormonal, environmental (such as a high amount of abdominal adipose tissue), and genetic factors and drugs (particularly glucocorticoids). We, therefore, evaluated the effects of the cholesteryl ester transfer protein (CETP) gene TaqIB polymorphism as well as of abdominal obesity on HDL-C levels in 78 male renal transplant recipients who were receiving azathioprine and/or ciclosporin A in combination with prednisone as immunosuppression. The patients were classified into genotypic groups according to the presence or absence of the restriction site (B1 allele or B2 allele, respectively). The distribution of CETP genotypes was similar to that previously described in the general population. Overall, HDL-C levels were 19 and 26% higher in B1B2 and B2B2 patients as compared with B1B1 homozygotes (p < 0.05), even after control for other lipid measurements. Patients with abdominal obesity (waist girth ≧93 cm) showed reduced HDL-C levels as compared with lean (waist girth <93 cm) patients (1.20 ± 0.28 vs. 1.42 ± 0.41 mmol/l, respectively, p < 0.01). Moreover, the HDL-C levels were markedly affected by the CETP TaqIB polymorphism in lean patients (+28 and +41% in B1B2 and B2B2 as compared with B1B1 patients, p < 0.05), but no significant difference was observed among obese patients. Significantly lower total cholesterol:HDL-C ratios were obtained in lean B2B2 homozygotes, suggesting that these patients could be less susceptible to atherosclerosis than lean B1B1 homozygotes. In addition, patients with the B1B1 genotype had more documented CHD as compared with patients carrying at least one B2 allele, supporting the protective effect of the B2 allele against CHD. In conclusion, considerable variation in HDL-C levels appears to be explained by the CETP TaqIB gene polymorphism in male renal transplant recipients, but this potential protective gene effect appears strongly reduced by concomitant abdominal obesity.

show abstract

HDL Subtractions Distribution in Renal Transplant Recipients: Lack of Evidence of a Reduction of HDL<sub>2</sub> Particles

Cited by 7 publications

References 24 publications

Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation

Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation

Changes in serum pigment epithelium-derived factor levels after kidney transplantation in patients with end-stage renal disease

HDL Cholesterol and TaqIB Cholesteryl Ester Transfer Protein Gene Polymorphism in Renal Transplant Recipients

Contact Info

Product

Resources

About